Estudo comparativo de eficácia terapêutica: dose única semanal x dose convencional diária de sulfato ferroso na anemia ferropriva

Detalhes bibliográficos
Ano de defesa: 2006
Autor(a) principal: Flavio Diniz Capanema
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Tese
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal de Minas Gerais
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: https://hdl.handle.net/1843/ECJS-84RQAC
Resumo: Introduction: the iron deficiency anemia is a serious problem of public health, over all in pregnant women and children, with major prevalence in developing countries and associated with low social and economics conditions. The knowledge about risk groups, related factors, diagnosis and early treatment could interfere with natural course of the illness preventing potential irreversible damages. The low adhesion of patients to the conventional treatment contributes for the maintenance of high prevalence rates. Some alternatives have been proposed in attempt of better control, being the use of iron in a weekly dose promising for the reduction of collateral effect, with greater adhesion and minor costs in the treatment. Objective: evaluate the effectiveness of single weekly dose of ferrous sulphate in the treatment of iron deficiency anemia compared to the traditional daily dose. Methods: randomized clinical trial conducted between 2001 and 2004 in children aged 0 to 6 years from day-care centers of Eastern Region of Belo Horizonte City. The study got the approval of Ethics Research Committee of Minas Gerais Federal University on April-25-01. In order to select anemic subjects to treatment, a screening was performed using portable hemoglobinometer (Hemocue®). Those with capillary hemoglobin (Hb) lower than 11.5 g/dL were submitted to laboratorial confirmation by eritrogram and ferritin tests. Hb =11.0 g/dL plus microcitose and/or hipocromia were utilized as criteria to define iron deficiency anemia. They were allocated for treatment with ferrous sulphate during 12 weeks, being the group 1 = 4mg/Kg daily and group 2 = 4mg/Kg weekly. In the end, eritrogram and ferritin were performed again. The sample was defined by the Bi-caudal method, with trustworthiness of 95% and power of 90% with minimum of 42 children per group. To compare averages in each group it was used Paired T Student Test and Anova Test for comparison of averages between the groups at the beginning and the end of treatment.Results: from 693 children initially selected, 93 fulfilled the criteria for treatment. In group 1 (daily) 43 had been treated / 2 losses and group 2 (weekly) 44 treated / 4 losses. In daily group was observed significant increases between initial Hb averages (9.77 ± 1.14 g/dL) and final (10.72 ± 0.70 g/dL) and between initial ferritin (17.37 ± 13.84) and final (35.87 ± 17.74). In weekly group it was also observed significant increases from initial Hb averages (9.71 ± 1.17 g/dL) to final (10.37 ± 0.95 g/dL) and from initial ferritin average (16.83 ± 10.45) to final (29.32 ± 15.91). In the end of treatment the comparison between groups showed no significant difference on average of Hb (p-value = 0.112) and ferritin (p-value = 0.073). Conclusion: both therapeutic schemes with ferrous sulphate had shown good reply in the treatment of iron deficiency anemia, with similar effectiviness in relation to increase of variables investigated.
id UFMG_745f14bb3f7dd43327e80e2c8e7a7a6e
oai_identifier_str oai:repositorio.ufmg.br:1843/ECJS-84RQAC
network_acronym_str UFMG
network_name_str Repositório Institucional da UFMG
repository_id_str
spelling 2019-08-09T15:27:05Z2025-09-08T23:02:15Z2019-08-09T15:27:05Z2006-10-04https://hdl.handle.net/1843/ECJS-84RQACIntroduction: the iron deficiency anemia is a serious problem of public health, over all in pregnant women and children, with major prevalence in developing countries and associated with low social and economics conditions. The knowledge about risk groups, related factors, diagnosis and early treatment could interfere with natural course of the illness preventing potential irreversible damages. The low adhesion of patients to the conventional treatment contributes for the maintenance of high prevalence rates. Some alternatives have been proposed in attempt of better control, being the use of iron in a weekly dose promising for the reduction of collateral effect, with greater adhesion and minor costs in the treatment. Objective: evaluate the effectiveness of single weekly dose of ferrous sulphate in the treatment of iron deficiency anemia compared to the traditional daily dose. Methods: randomized clinical trial conducted between 2001 and 2004 in children aged 0 to 6 years from day-care centers of Eastern Region of Belo Horizonte City. The study got the approval of Ethics Research Committee of Minas Gerais Federal University on April-25-01. In order to select anemic subjects to treatment, a screening was performed using portable hemoglobinometer (Hemocue®). Those with capillary hemoglobin (Hb) lower than 11.5 g/dL were submitted to laboratorial confirmation by eritrogram and ferritin tests. Hb =11.0 g/dL plus microcitose and/or hipocromia were utilized as criteria to define iron deficiency anemia. They were allocated for treatment with ferrous sulphate during 12 weeks, being the group 1 = 4mg/Kg daily and group 2 = 4mg/Kg weekly. In the end, eritrogram and ferritin were performed again. The sample was defined by the Bi-caudal method, with trustworthiness of 95% and power of 90% with minimum of 42 children per group. To compare averages in each group it was used Paired T Student Test and Anova Test for comparison of averages between the groups at the beginning and the end of treatment.Results: from 693 children initially selected, 93 fulfilled the criteria for treatment. In group 1 (daily) 43 had been treated / 2 losses and group 2 (weekly) 44 treated / 4 losses. In daily group was observed significant increases between initial Hb averages (9.77 ± 1.14 g/dL) and final (10.72 ± 0.70 g/dL) and between initial ferritin (17.37 ± 13.84) and final (35.87 ± 17.74). In weekly group it was also observed significant increases from initial Hb averages (9.71 ± 1.17 g/dL) to final (10.37 ± 0.95 g/dL) and from initial ferritin average (16.83 ± 10.45) to final (29.32 ± 15.91). In the end of treatment the comparison between groups showed no significant difference on average of Hb (p-value = 0.112) and ferritin (p-value = 0.073). Conclusion: both therapeutic schemes with ferrous sulphate had shown good reply in the treatment of iron deficiency anemia, with similar effectiviness in relation to increase of variables investigated.Universidade Federal de Minas GeraisSaúde da CriançaAnemiaSulfato FerrosoDeficiência de FerroTratamentoSaúde PúblicaAnemiaSulfato ferrosoPaíses em desenvolvimentoFatores socioeconômicosSaúde públicaAnemia ferropriva/terapiaDeficiência de ferroEstudo comparativoDose únicaEnsaio clínicoPediatriaEstudo comparativo de eficácia terapêutica: dose única semanal x dose convencional diária de sulfato ferroso na anemia ferroprivainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisFlavio Diniz Capanemainfo:eu-repo/semantics/openAccessporreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGJoel Alves LamounierRocksane de Carvalho NortonCarlos Roberto Nogueira de AlmeidaJosé Eduardo Dutra de OliveiraMarcelo Militão AbrantesRegina Lunardi RochaIntrodução: a anemia por deficiência de ferro constitui sério problema de saúde pública, sobretudo em gestantes e crianças, com prevalência maior nos países em desenvolvimento e associada a condições sócio-econômicas desfavoráveis. O reconhecimento dos grupos de risco, fatores associados, diagnóstico e tratamento precoce interferem no curso natural da doença, prevenindo agravos potencialmente irreversíveis. A baixa adesão ao tratamento convencional contribui para a manutenção das altas taxas de prevalência. Várias alternativas têm sido propostas na tentativa de melhor controle, sendo o uso de ferro em dose semanal promissor pela redução de efeitos colaterais, maior adesão e menor custo no tratamento. Objetivo: avaliar a eficácia do esquema terapêutico com dose única semanal de sulfato ferroso no tratamento da anemia ferropriva comparado ao esquema tradicional em dose diária.Métodos: ensaio clínico randomizado realizado entre 2001 e 2004 em crianças de 0 a 6 anos, pertencentes a creches da Regional Leste de Belo Horizonte, utilizando-se hemoglobinômetro portátil (Hemocue®) para triagem. Aquelas com hemoglobina (Hb) digital < 11,5 g/dL foram submetidas a confirmação laboratorial (eritrograma e ferritina), sendo definidas como anêmicas as portadoras de Hb =11,0g/dL com microcitose e/ou hipocromia e alocadas em dois grupos para tratamento com sulfato ferroso por 12 semanas, sendo o grupo 1 = 4mg/Kg Fe++ diário e grupo 2 = 4mg/Kg Fe++ semanal. Ao final, novos eritrograma e ferritina foram realizados. Definição da amostra pelo método Bi-caudal com confiabilidade=95% e poder=90% com mínimo de 42 crianças/grupo. Utilizou-se Teste T pareado para comparação de médias para cada grupo e Anova para comparação de médias entre os grupos ao início e término do tratamento. O estudo obteve a aprovação do Comitê de Ética em Pesquisa da UFMG em 25/04/01.Resultados: das 693 crianças selecionadas 93 delas preencheram critérios para tratamento, sendo o grupo 1 (diário) composto por 43 crianças / 2 perdas e o grupo 2 (semanal) por 44 crianças / 4 perdas. No esquema diário foram observados aumentos significativos entre a média de Hb inicial (9,77 ± 1,14 g/dL) e final (10,72 ± 0,70 g/dL) e entre a ferritina inicial (17,37 ± 13,84) e final (35,87 ± 17,74). No grupo de dose semanal também foram observados aumentos significativos entre a média de Hb inicial (9,71 ± 1,17 g/dL) e final (10,37 ± 0,95 g/dL) e entre a ferritina inicial (16,83 ± 10,45) e final (29,32 ± 15,91). A comparação entre os grupos ao final do tratamento mostrou não haver diferença significativa em relação a Hb (valor-p = 0,112) e ferritina (valor-p = 0,073).Conclusão: os dois esquemas avaliados apresentaram resposta adequada ao tratamento da anemia ferropriva com sulfato ferroso e eficácia semelhante em relação às variáveis estudadas.UFMGORIGINALfl_vio_diniz_capanema.pdfapplication/pdf2491592https://repositorio.ufmg.br//bitstreams/c338d6b9-ac2a-48cb-8f0e-eb0c56b07831/downloadf9dcf9872d995d302209e18a58ee5819MD51trueAnonymousREADTEXTfl_vio_diniz_capanema.pdf.txttext/plain124249https://repositorio.ufmg.br//bitstreams/e3010fc5-9140-467a-9588-b9f2b69fda11/download662ee0f83a79079601dc1aa42911be1eMD52falseAnonymousREAD1843/ECJS-84RQAC2025-09-08 20:02:15.168open.accessoai:repositorio.ufmg.br:1843/ECJS-84RQAChttps://repositorio.ufmg.br/Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2025-09-08T23:02:15Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false
dc.title.none.fl_str_mv Estudo comparativo de eficácia terapêutica: dose única semanal x dose convencional diária de sulfato ferroso na anemia ferropriva
title Estudo comparativo de eficácia terapêutica: dose única semanal x dose convencional diária de sulfato ferroso na anemia ferropriva
spellingShingle Estudo comparativo de eficácia terapêutica: dose única semanal x dose convencional diária de sulfato ferroso na anemia ferropriva
Flavio Diniz Capanema
Anemia
Sulfato ferroso
Países em desenvolvimento
Fatores socioeconômicos
Saúde pública
Anemia ferropriva/terapia
Deficiência de ferro
Estudo comparativo
Dose única
Ensaio clínico
Pediatria
Saúde da Criança
Anemia
Sulfato Ferroso
Deficiência de Ferro
Tratamento
Saúde Pública
title_short Estudo comparativo de eficácia terapêutica: dose única semanal x dose convencional diária de sulfato ferroso na anemia ferropriva
title_full Estudo comparativo de eficácia terapêutica: dose única semanal x dose convencional diária de sulfato ferroso na anemia ferropriva
title_fullStr Estudo comparativo de eficácia terapêutica: dose única semanal x dose convencional diária de sulfato ferroso na anemia ferropriva
title_full_unstemmed Estudo comparativo de eficácia terapêutica: dose única semanal x dose convencional diária de sulfato ferroso na anemia ferropriva
title_sort Estudo comparativo de eficácia terapêutica: dose única semanal x dose convencional diária de sulfato ferroso na anemia ferropriva
author Flavio Diniz Capanema
author_facet Flavio Diniz Capanema
author_role author
dc.contributor.author.fl_str_mv Flavio Diniz Capanema
dc.subject.por.fl_str_mv Anemia
Sulfato ferroso
Países em desenvolvimento
Fatores socioeconômicos
Saúde pública
Anemia ferropriva/terapia
Deficiência de ferro
Estudo comparativo
Dose única
Ensaio clínico
Pediatria
topic Anemia
Sulfato ferroso
Países em desenvolvimento
Fatores socioeconômicos
Saúde pública
Anemia ferropriva/terapia
Deficiência de ferro
Estudo comparativo
Dose única
Ensaio clínico
Pediatria
Saúde da Criança
Anemia
Sulfato Ferroso
Deficiência de Ferro
Tratamento
Saúde Pública
dc.subject.other.none.fl_str_mv Saúde da Criança
Anemia
Sulfato Ferroso
Deficiência de Ferro
Tratamento
Saúde Pública
description Introduction: the iron deficiency anemia is a serious problem of public health, over all in pregnant women and children, with major prevalence in developing countries and associated with low social and economics conditions. The knowledge about risk groups, related factors, diagnosis and early treatment could interfere with natural course of the illness preventing potential irreversible damages. The low adhesion of patients to the conventional treatment contributes for the maintenance of high prevalence rates. Some alternatives have been proposed in attempt of better control, being the use of iron in a weekly dose promising for the reduction of collateral effect, with greater adhesion and minor costs in the treatment. Objective: evaluate the effectiveness of single weekly dose of ferrous sulphate in the treatment of iron deficiency anemia compared to the traditional daily dose. Methods: randomized clinical trial conducted between 2001 and 2004 in children aged 0 to 6 years from day-care centers of Eastern Region of Belo Horizonte City. The study got the approval of Ethics Research Committee of Minas Gerais Federal University on April-25-01. In order to select anemic subjects to treatment, a screening was performed using portable hemoglobinometer (Hemocue®). Those with capillary hemoglobin (Hb) lower than 11.5 g/dL were submitted to laboratorial confirmation by eritrogram and ferritin tests. Hb =11.0 g/dL plus microcitose and/or hipocromia were utilized as criteria to define iron deficiency anemia. They were allocated for treatment with ferrous sulphate during 12 weeks, being the group 1 = 4mg/Kg daily and group 2 = 4mg/Kg weekly. In the end, eritrogram and ferritin were performed again. The sample was defined by the Bi-caudal method, with trustworthiness of 95% and power of 90% with minimum of 42 children per group. To compare averages in each group it was used Paired T Student Test and Anova Test for comparison of averages between the groups at the beginning and the end of treatment.Results: from 693 children initially selected, 93 fulfilled the criteria for treatment. In group 1 (daily) 43 had been treated / 2 losses and group 2 (weekly) 44 treated / 4 losses. In daily group was observed significant increases between initial Hb averages (9.77 ± 1.14 g/dL) and final (10.72 ± 0.70 g/dL) and between initial ferritin (17.37 ± 13.84) and final (35.87 ± 17.74). In weekly group it was also observed significant increases from initial Hb averages (9.71 ± 1.17 g/dL) to final (10.37 ± 0.95 g/dL) and from initial ferritin average (16.83 ± 10.45) to final (29.32 ± 15.91). In the end of treatment the comparison between groups showed no significant difference on average of Hb (p-value = 0.112) and ferritin (p-value = 0.073). Conclusion: both therapeutic schemes with ferrous sulphate had shown good reply in the treatment of iron deficiency anemia, with similar effectiviness in relation to increase of variables investigated.
publishDate 2006
dc.date.issued.fl_str_mv 2006-10-04
dc.date.accessioned.fl_str_mv 2019-08-09T15:27:05Z
2025-09-08T23:02:15Z
dc.date.available.fl_str_mv 2019-08-09T15:27:05Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/1843/ECJS-84RQAC
url https://hdl.handle.net/1843/ECJS-84RQAC
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Universidade Federal de Minas Gerais
publisher.none.fl_str_mv Universidade Federal de Minas Gerais
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMG
instname:Universidade Federal de Minas Gerais (UFMG)
instacron:UFMG
instname_str Universidade Federal de Minas Gerais (UFMG)
instacron_str UFMG
institution UFMG
reponame_str Repositório Institucional da UFMG
collection Repositório Institucional da UFMG
bitstream.url.fl_str_mv https://repositorio.ufmg.br//bitstreams/c338d6b9-ac2a-48cb-8f0e-eb0c56b07831/download
https://repositorio.ufmg.br//bitstreams/e3010fc5-9140-467a-9588-b9f2b69fda11/download
bitstream.checksum.fl_str_mv f9dcf9872d995d302209e18a58ee5819
662ee0f83a79079601dc1aa42911be1e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)
repository.mail.fl_str_mv repositorio@ufmg.br
_version_ 1862106050844426240